Investor Presentaiton

INVESTOR 20 DAY 23 4 What kind of therapy is best for me? Breast Cancer Expanded patient eligibility for targeted therapy through promoter methylation Epigenomics unlocks mechanisms of regulation that are invisible to genomic testing BRCA1 Samples BRCA1 Promoter Methy lated Loci ~24% of TNBC patients are associated with promoter methylation¹ Without analyzing both genomic and epigenomic alterations, patients potentially eligible for PARPi therapies would be missed² GUARDANT™ PARPI Poly adenosine diphosphate-ribose polymerase inhibitor; TNBC-triple negative breast cancer. 1. Glodzik D et al. Nat Commun. 2020. 2. Coyne et al. Onco Targets Ther 2022. 37

View entire presentation